{"id":673,"date":"2024-08-30T22:59:36","date_gmt":"2024-08-30T20:59:36","guid":{"rendered":"https:\/\/studienportal-endometriumkrebs.de\/latest-from-research-and-practice\/"},"modified":"2026-07-20T16:52:48","modified_gmt":"2026-07-20T14:52:48","slug":"latest-from-research-and-practice","status":"publish","type":"page","link":"https:\/\/studienportal-endometriumkrebs.de\/en\/latest-from-research-and-practice\/","title":{"rendered":"Latest from research and practice"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

News<\/strong>
Latest from research and practice<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n
\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

New Findings from ASCO 2026<\/a><\/h3><\/header>
\n

As part of the NOGGO Gynecological Oncology Update, the most important studies from this year’s ASCO Congress were presented. RUBY Study: Long-term Benefit of Immunotherapy Confirmed New long-term data from...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

DESTINY-ENDOMETRIAL01<\/a><\/h3><\/header>
\n

DESTINY-ENDOMETRIAL01 THERAPY STUDY COMBINING TRASTUZUMAB DERUXTECAN (T-DXD) AND RILVEGOSTOMIG OR PEMBROLIZUMAB IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER The DESTINY-Endometrial01 is a global, randomized (treatment assignment for the individual...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

PYNNACLE STUDY<\/a><\/h3><\/header>
\n

PYNNACLE STUDY THERAPY STUDY TO EVALUATE THE EFFICACY AND SAFETY OF THE NEW ACTIVE SUBSTANCE REZATAPOPT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS The PYNNACLE study is a...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S35 \u2013 Expression XXI \u2013 (21)<\/a><\/h3><\/header>
\n

NOGGO S35 \/ Expression XXI \u2013 (21) \/ SARA Study Survey study on the quality of life of patients with endometrial cancer The SARA study is a Europe-wide survey study...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S33 \u2013 Expression XX (20)<\/a><\/h3><\/header>
\n

NOGGO S33 \u2013 Expression XX (20) Survey of female patients with gynecological tumor diseases on delivering bad news Delivering bad news is an essential part of daily medical practice, especially...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S30 \u2013 EXPRESSION XVIII (18)<\/a><\/h3><\/header>
\n

NOGGO S30 \u2013 EXPRESSION XVIII (18) International survey on the impact of crises on patients with gynaecological cancers Fear is a central issue for cancer patients with gynaecological diseases and...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S20 \/ ENGOT-gyn4 \u2013 Expression IX (9)<\/a><\/h3><\/header>
\n

NOGGO S20 \/ ENGOT-gyn4 \u2013 Expression IX \u2013 (9) Long-term survival with gynecological cancer \/ Long-term survivors with gynecological cancers Based on the experience with Expression VI \u2013 Carolin meets...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO S18 \/ EMRISK (Recruitment Completed)<\/a><\/h3><\/header>
\n

NOGGO S18 \u2013 EMRISK Recruitment of patients with endometrial cancer has been completed for this study. Development of a Risk Prediction Model for Nausea and Vomiting During Chemotherapy What is...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

ENGOT-EN29 \/ TroFuse-033<\/a><\/h3><\/header>
\n

ENGOT-EN29 \/ TroFuse-033 Therapy study on the combination of Sacituzumab Tirumotecan (SAC-TMT) and Pembrolizumab as maintenance therapy in patients with advanced or recurrent endometrial cancer The TroFuse-033 study is an...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

NOGGO-EN17 \/ DUOLife<\/a><\/h3><\/header>
\n

DUOLife Observational study on first-line therapy in patients with advanced or recurrent endometrial cancer The DUOLife study is a non-interventional observational study. This means that patients receive an already planned...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Novel treatment options for the management of advanced-stage endometrial cancer<\/a><\/h3><\/header>
\n

Novel treatment options for the management of advanced-stage endometrial cancer In this special presentation from IGCS Advances & Updates, Linda Ryan, a survivor of metastatic recurrent cervical cancer and patient...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

ASCO Results on Endometrial Cancer<\/a><\/h3><\/header>
\n

ASCO Results on Endometrial Cancer Yesterday, the 26th NOGGO Update on Gynecological Oncology took place, where important studies on endometrial cancer from ASCO 2025 were presented. We were on site...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

ENGOT-EN20 \/ XPORT-EC-042 (Recruitment completed)<\/a><\/h3><\/header>
\n

ENGOT-EN20 \/ XPORT-EC-042Recruitment for the XPORT study was completed in January 2026. Clinical trial with Selinexor as maintenance therapy following systemic therapy in patients with p53 wild-type, advanced or recurrent...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n

AGO-OP.6 \u2013 ECLAT<\/a><\/h3><\/header>
\n

AGO-OP.6 \u2013 ECLAT Study for patients with stage I or II endometrial cancer at high risk of recurrence \u2013 a multicenter, prospective, randomized controlled trial What is being investigated in...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Prof. Sehouli from Charit\u00e9: New treatment option for endometrial cancer patients<\/a><\/h3><\/header>
\n

Prof. Sehouli from Charit\u00e9: New treatment option for endometrial cancer patients Encouraging news for those affected by uterine cancer: In a few weeks, the range of treatment options will expand....<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

New Hope for Patients with Advanced Endometrial Carcinoma<\/a><\/h3><\/header>
\n

New Hope for Patients with Advanced Endometrial Carcinoma A new study by Karyopharm Therapeutics offers promising results for women with advanced or recurrent TP53 wild-type endometrial carcinoma. The SIENDO study,...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Cancer Podcast for Physicians \u2013 Endometrial Carcinoma \u2013 a Tumor with an Increasing Incidence<\/a><\/h3><\/header>
\n

Cancer Podcast for Physicians \u2013 Endometrial Carcinoma \u2013 a Tumor with an Increasing Incidence New episode: the cancer podcast with Dr. med. Robert Armbrust and Prof. Dr. med. Dr. h.c....<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article>

\n
\n
<\/i><\/a><\/div>
\n \"\"\n <\/div>\n <\/div>

Endometrial Cancer: What is the best therapy today? What are the latest studies? Lecture by Dr. Robert Armbrust<\/a><\/h3><\/header>
\n

Endometrial Cancer: What is the best therapy today? What are the latest studies? Lecture by Dr. Robert Armbrust As part of the 2023 Study Day, Dr. Robert Armbrust from Charit\u00e9...<\/p>Read more<\/a><\/div>\n <\/div><\/div><\/div>\n <\/div>\n <\/article><\/div>\n

<\/div>\n <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

NewsLatest from research and practice Neue Erkenntnisse vom ASCO 2026 Im Rahmen des NOGGO-Updates Gyn\u00e4kologische Onkologie wurden die wichtigsten Studien zum diesj\u00e4hrigen ASCO-Kongress vorgestellt.\u00a0 RUBY-Studie: Langfristiger Nutzen der Immuntherapie best\u00e4tigt Neue Langzeitdaten der\u00a0RUBY-Studie\u00a0best\u00e4tigen den anhaltenden Nutzen der Immuntherapie\u00a0Dostarlimab\u00a0in Kombination mit… Read more DESTINY-ENDOMETRIAL01 DESTINY-ENDOMETRIAL01 THERAPIESTUDIE ZUR KOMBINATION VON TRASTUZUMAB DERUXTECAN (T-DXD) UND RILVEGOSTOMIG ODER PEMBROLIZUMAB […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-673","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/pages\/673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/comments?post=673"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/pages\/673\/revisions"}],"predecessor-version":[{"id":674,"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/pages\/673\/revisions\/674"}],"wp:attachment":[{"href":"https:\/\/studienportal-endometriumkrebs.de\/en\/wp-json\/wp\/v2\/media?parent=673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}